# GDNF in ideopathicParkinsons Disease

> **NCT03652363** · PHASE2 · COMPLETED · sponsor: **North Bristol NHS Trust** · enrollment: 42 (actual)

## Conditions studied

- Idiopathic Parkinson Disease

## Interventions

- **DRUG:** glial cell line-derived neurotrophic factor

## Key facts

- **NCT ID:** NCT03652363
- **Lead sponsor:** North Bristol NHS Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-25
- **Primary completion:** 2015-03-13
- **Final completion:** 2016-04-01
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2018-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03652363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03652363, "GDNF in ideopathicParkinsons Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03652363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*